News
ACOG
8.47
-1.17%
-0.10
Alpha Cognition management to meet virtually with B. Riley
TipRanks · 5d ago
Weekly Report: what happened at ACOG last week (0914-0918)?
Weekly Report · 6d ago
Major Investor Makes Bold Move on Alpha Cognition Inc.
TipRanks · 09/17 02:02
Weekly Report: what happened at ACOG last week (0907-0911)?
Weekly Report · 09/14 10:19
Weekly Report: what happened at ACOG last week (0831-0904)?
Weekly Report · 09/07 10:12
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 09/01 16:00
Weekly Report: what happened at ACOG last week (0824-0828)?
Weekly Report · 08/31 10:19
Weekly Report: what happened at ACOG last week (0817-0821)?
Weekly Report · 08/24 10:20
Alpha Cognition Earnings Call: ZUNVEYL Drives Momentum
TipRanks · 08/23 00:22
Alpha Cognition rises as B. Riley initiates at Buy on Alzheimer’s drug
Seeking Alpha · 08/20 16:39
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 08/20 11:51
Alpha Cognition Price Target Announced at $21.00/Share by B. Riley Securities
Dow Jones · 08/20 10:59
B. Riley Securities Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $21
Benzinga · 08/20 10:49
Alpha Cognition initiated with a Buy at B. Riley
TipRanks · 08/20 01:15
Alpha Cognition Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/17 16:32
Alpha Cognition Price Target Raised to $20.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 08/17 16:32
HC Wainwright & Co. Maintains Buy on Alpha Cognition, Raises Price Target to $20
Benzinga · 08/17 16:22
Analysts Conflicted on These Healthcare Names: Alpha Cognition Inc (ACOG) and TScan Therapeutics (TCRX)
TipRanks · 08/17 15:40
Alpha Cognition price target raised to $20 from $18 at H.C. Wainwright
TipRanks · 08/17 15:25
Weekly Report: what happened at ACOG last week (0810-0814)?
Weekly Report · 08/17 10:21
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.